[Current therapeutic use of gamma globulin preparations]

Non-specific intramuscular and especially intravenous immunoglobulins became an important part of the treatment of two different immunopathological states. They are used as substitution therapy in absolute or relative shortage of specific antibodies in primary humoral immunodeficiencies--especially various types of hypogammaglobulinemia, and secondary humoral immunodeficiencies--lymphatic system malignancies, serious septic states etc. The second indication area of intravenous immunoglobulins is based on the proved abilities of intravenous immunoglobulins to suppress the production of antibodies (and autoantibodies), and to block phagocytic cells. Intravenous gammaglobulin treatment is generally used in idiopathic thrombocytopenic purpura and Kawasaki disease. The results of the treatment of autoimmune diseases of connective tissue, hematological and nervous system diseases are also promising. Side-effects of treatment are not frequent, but anaphylactic reactions may be fatal.